# IR System Add-ons (Microplastics)

Canonical: https://abierto.us/opportunities/noifda134639

- Solicitation number: NOI-FDA-134639
- Notice type: Presolicitation
- Status: Closed. Deadline was August 13, 2026 at 9:00 AM EDT
- Department: Department of Health and Human Services
- Agency: Food and Drug Administration
- Contracting office: FDA Office of Acq Grant SVCS (75F401)
- NAICS: 334516 Analytical Laboratory Instrument Manufacturing
- Product or service code: 6640 Laboratory Equipment and Supplies
- Place of performance: College Park, Maryland
- First posted: July 30, 2026
- Last posted: July 30, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/4249dac313e6490fabed48db9ac025d8/view

## Description

Pursuant to RFO 5.101(c)(4)(vii), the following identifies the intended source and explains why competition is not practicable for this requirement.

**Intended Contractor:** Photothermal Spectroscopy Corp. 325 Chapala St Santa Barbara, CA 93101 CAGE Code: 83PQ8 The basis for limiting this solicitation to a single source is that only one source is reasonably available, consistent with RFO 13.101(b) and the single-source standard at RFO 12.201-1(c).

Photothermal Spectroscopy Corp?“PSC” is the one and only?supplier that can meet the performance requirements?outlined in the?Statement of?Work.?The?counter-propagating mode upgrade?must be 100% compatible with the existing?Photothermal?mIRageLS?to provide a seamless integration and?establish?full?system communication?and control?through?the?single, existing?software currently at FDA.?PSC owns the patent for intellectual property protecting the O-PTIR technology and its associated capabilities.

O-PTIR is protected by multiple patents and is exclusively available from Photothermal Spectroscopy. PSC will be the only provider to support the FDA in this requirement of the necessary parts and knowledgeable installation team to ensure?100% compatibility?of?the upgrade?with?the current FDA instrument.?Photothermal is a US company?and is a registered small business.?A Brand Name?acquisition is recommended, since only one provider meets the requirements for the acquisition.? A written single-source justification has been prepared and approved in accordance with RFO 12.201-1(c) and RFO 13.101(b).

## Publications

- July 30, 2026: Presolicitation, due August 13, 2026 at 9:00 AM EDT. Notice 4249dac313e6490fabed48db9ac025d8. https://sam.gov/workspace/contract/opp/4249dac313e6490fabed48db9ac025d8/view

## Points of contact

- Aarati Singal, aarati.singal@fda.hhs.gov
- Sarah Hussain, Sarah.Hussain@fda.hhs.gov

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/noifda134639.